In this article, we will discuss Durvalumab (Warnings-28). So, let’s get started.
Other Immune-Mediated Adverse Reactions
- The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than 1% each in patients who received Durvalumab or were reported with the use of other PD-1/PD-L1 blocking antibodies.
- Cardiac/vascular: Myocarditis, pericarditis, vasculitis.